Skip to main content
SpringerLink
Log in

Which radionuclides will nuclear oncology need tomorrow?

  • Editorial
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Notes

  1. The name ARRONAX also refers to Professor Aronnax, a character in the novel Twenty Thousand Leagues Under the Sea by the famous French writer Jules Verne, who was born in Nantes in 1828.

References

  1. Von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology 2006;238:405–22

    Article  Google Scholar 

  2. Couturier O, Luxen A, Chatal JF, Vuillez JP, Rigo P, Hustinx R. Fluorinated tracers for imaging cancer with positron emission tomography. Eur J Nucl Med Mol Imaging 2004;31:1182–206

    Article  PubMed  CAS  Google Scholar 

  3. Chatal JF. Radioimmunotherapy, a new breakthrough in the treatment of follicular non-Hodgkin’s lymphoma: the European perspective. Cancer Biother Radiopharm 2006;21:1–4

    Article  PubMed  CAS  Google Scholar 

  4. Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005;23:5696–704

    Article  PubMed  CAS  Google Scholar 

  5. Radford JA, Ketterer N, Sebban C. Ibritumomab tiuxetan (Zevalin) therapy is feasible and safe for the treatment of patients with advanced B-cell follicular NHL in first remission: interim analysis for safety of multicenter, phase III clinical trial. Blood 2003;102:408a

    Article  Google Scholar 

  6. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754–62

    Article  PubMed  CAS  Google Scholar 

  7. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980;303:1189–94

    Article  PubMed  CAS  Google Scholar 

  8. Moertel CM, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519–23

    Article  PubMed  CAS  Google Scholar 

  9. Bukowski RM, Tangen CM, Peterson RF, Taylor SA, Rinehart JJ, Eyre HJ, et al. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. Cancer 1994;73:1505–8

    Article  PubMed  CAS  Google Scholar 

  10. Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol 2005;23:6763–70

    Article  PubMed  CAS  Google Scholar 

  11. Chatal JF, Campion L, Kraeber-Bodere F, Bardet S, Vuillez JP, Charbonnel B et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006;24:1705–1711

    Google Scholar 

  12. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 2006;24:115–22

    Article  PubMed  CAS  Google Scholar 

  13. Lee FT, Scott AM. Immuno-PET for tumor targeting. J Nucl Med 2003;44:1282–83

    PubMed  CAS  Google Scholar 

  14. Verel I, Visser GW, van Dongen GA. The promise of immuno-PET in radioimmunotherapy. J Nucl Med 2005;46(Suppl 1):164s–71s

    PubMed  Google Scholar 

  15. DeNardo GL, DeNardo SJ, O’Donnell RT, Kroger LA, Kukis DL, Meares CF, et al. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin’s lymphoma. Clin Lymphoma 2000;1:118–26

    Article  PubMed  CAS  Google Scholar 

  16. de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):13s–7s

    PubMed  Google Scholar 

  17. Couturier O, Supiot S, Degraef-Mougin M, Faivre-Chauvet A, Carlier T, Chatal JF, et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging 2005;32:601–14

    Article  PubMed  CAS  Google Scholar 

  18. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002;100:1233–9

    PubMed  CAS  Google Scholar 

  19. Sharkey RM, Cardillo TM, Rossi EA, Chang C-H, Karacay H, McBride WJ, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nature Med 2005;11:1250–5

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre de Recherche sur le Cancer, Université de Nantes, Inserm, U601, Nantes, France

    Jacques Barbet & Jean-François Chatal

  2. Subatech, UMR 6457, Ecole des Mines de Nantes, CNRS/IN2P3, Université de Nantes, Nantes, France

    François Gauché & Jacques Martino

Authors
  1. Jacques Barbet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-François Chatal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. François Gauché
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jacques Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-François Chatal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barbet, J., Chatal, JF., Gauché, F. et al. Which radionuclides will nuclear oncology need tomorrow?. Eur J Nucl Med Mol Imaging 33, 627–630 (2006). https://doi.org/10.1007/s00259-006-0116-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-006-0116-4

Search

Navigation